论文部分内容阅读
目的探讨非鼻腔及鼻咽部CD5 6 +与CD5 6 -T细胞淋巴瘤与EB病毒的相关性。方法收集 11例CD5 6 +与 14例CD5 6 -非鼻腔及鼻咽部淋巴瘤 ,用免疫组化SP法确定瘤细胞本质 ,使用的抗体包括CD3、CD2 0、CD4 5RO、CD5 6等。用原位杂交法检测EB病毒编码的RNA(EBER1/ 2 )。结果E BER1/ 2检出率在CD5 6 +的TCL中占 18.2 % (2 / 11) ,在CD5 6 -的TCL中占 2 8.6 % (4/ 14 ) ,两者比较无统计学差异 (P =0 .4 5 2 )。结论非鼻腔及鼻咽部TCL中EBV感染与CD5 6的表达无关
Objective To investigate the relationship between non-nasal and nasopharyngeal CD5 6 + and CD5 6-T cell lymphoma and Epstein-Barr virus. Methods 11 cases of CD5 6 + and 14 cases of CD5 6 - non-nasal and nasopharyngeal lymphoma were collected. The nature of tumor cells was determined by immunohistochemical SP method. The antibodies used included CD3, CD20, CD4 5RO and CD5 6. Epstein-Barr virus-encoded RNA (EBER1 / 2) was detected by in situ hybridization. Results The detection rate of E BER1 / 2 was 18.2% (2/11) in TCL of CD5 6 + and 8.62% (4/14) in TCL of CD5 6 -, the difference was not statistically significant (P = 0 .4 5 2). Conclusion EBV infection in non-nasal and nasopharyngeal TCL has nothing to do with the expression of CD5 6